Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
15.04. | Study warns of chronic kidney disease timebomb | ||
15.04. | After ph3 win, Roche eyes earlier use of Columvi in DLBCL | ||
15.04. | EMA finds no suicide risk with GLP-1 diabetes, obesity drugs | ||
12.04. | BioMarin's Voxzogo shows promise in hypochondroplasia | ||
12.04. | TORL rakes in $158m for ADCs, and other bio financings | ||
12.04. | AZ shareholders back CEO Soriot's pay package, amid dissent | ||
12.04. | Ex-broadcaster Paxman hands Parkinson's wish list to UK PM | ||
12.04. | Novartis adds clinical-stage protein degrader from Arvinas | ||
11.04. | NICE backs AbbVie's oral therapy for migraine prevention | ||
11.04. | US accuses Regeneron of fraud in Eylea price reporting | ||
11.04. | FDA puts breakthrough tag on Roche, Lilly Alzheimer's test | ||
11.04. | EU pharma reform package clears key Parliament vote | ||
11.04. | Vertex wagers $4.9bn on Alpine Immune kidney disease therapy | ||
10.04. | Roche gets EU okay for first HER2-low test kit | ||
10.04. | e-therapeutics is latest UK biotech to seek AIM de-listing | ||
10.04. | UK calls time-out on post-Brexit rules opposed by industry | ||
10.04. | Essential adds neuroblastoma drug with Renaissance buy | ||
10.04. | Bayer, Google partner on AI for time-pressed radiologists | ||
09.04. | Ubie AI aims to improve diagnosis of rare disease Cushing's | ||
09.04. | UK survey finds deep ethnic divisions in cancer diagnosis | ||
09.04. | NHS trust bids to take license for abandoned gene therapy | ||
09.04. | Ex-Karuna team launch Seaport with $100m for psychiatry meds | ||
09.04. | Study points to weaknesses in FDA accelerated approval path | ||
08.04. | Enhertu gets FDA nod for tumour-agnostic HER2 cancers | ||
08.04. | Ionis, Arrowhead hail data with triglyceride drugs at ACC |